Diabetes

Diabetes mellitus, a chronic metabolic disorder characterized by dysregulated glucose homeostasis, remains a significant global health challenge. Alfa Cytology has dedicated extensive research into uncovering novel therapeutic strategies to combat this debilitating disease. One particularly promising avenue lies in the targeted modulation of the Poly(ADP-ribose) Polymerase (PARP) pathway.

PARP as a Therapeutic Target for Diabetes

PARP enzymes, particularly PARP-1, play a crucial role in cellular processes such as DNA damage repair, gene transcription, and cell death. Emerging evidence suggests that PARP dysregulation is intimately linked to the pathogenesis of both type 1 and type 2 diabetes. Hyperglycemia-induced oxidative stress can lead to excessive PARP activation, which in turn can deplete cellular NAD+ stores and trigger beta-cell dysfunction and apoptosis.

Fig. 1 An overview of the PARP1-mediated pathologies of diabetes. (Dadheech N., et al. 2022)

PARP Inhibitor Development for Diabetes

Interestingly, PARP inhibition has been shown to confer significant protective effects in various experimental models of diabetes. Studies have demonstrated that pharmacological inhibition of PARP can promote beta-cell differentiation, enhance insulin secretion, and mitigate the devastating complications associated with diabetes, including neuropathy, nephropathy, and retinopathy.

Our Services

At Alfa Cytology, we pride ourselves on our world-class expertise and cutting-edge capabilities in preclinical drug development for diabetes therapies.

Our comprehensive service offerings include:

In Vitro Evaluation

Our team assess the efficacy and safety of PARP inhibitors in modulating pancreatic beta-cell function, survival, and differentiation using both human and rodent cell lines.

In Vivo Modeling

We utilize well-established animal models of diabetes, including diet-induced obesity models, to evaluate the therapeutic potential of PARP inhibitors in vivo.

Mechanistic Investigations

Through functional assays, we delve into the underlying mechanisms by which PARP inhibition exerts its effects on β cell homeostasis and whole-body glucose regulation.

Pharmacokinetic and Toxicology Studies

Alfa Cytology's expert pharmacologists and toxicologists rigorously assess the pharmacokinetic profile, biodistribution, and safety of PARP inhibitor candidates.

Our Technology Platform

Alfa Cytology's team of dedicated scientists and drug development experts are committed to advancing the therapeutic potential of PARP inhibitors for the management of diabetes. If you would like to discuss how our comprehensive preclinical services can support your research initiatives, please don't hesitate to contact us.

For research use only. Not intended for any clinical use.